RWRyan Watkins

Ryan Watkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryan Watkins has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Needs and artificial intelligence

    by Soheil Human, Ryan Watkins

    Throughout our history, we, Homo sapiens, have used technologies to better satisfy ourneeds. The relation betweenneedsandtechnologyis so fundamental that the US National Research Council defines the distinguishing characteristic of technology as its goal “to make modifications in the world [in order] to meet human needs” [1]. Artificial intelligence (AI) is one of the most promising emerging technologies of our time. Similar to other technologies, AI is expected by many “to meet [human] needs”. In this article, we reflect on the relationship betweenneedsand AI, and call for the realization ofneeds-awareAI systems. We argue that re-thinkingneedsfor,through,by, andwithAI can be a very useful means towards the development of realistic approaches for sustainableHuman-aware,Accountable,Lawful, andEthical (HALE) AI systems. We discuss some of the most critical gaps, barriers, enablers, and drivers of co-creating future AI-based sociotechnical systems in which [human]needsare well considered and met. Finally, we provide an overview of potential challenges and considerations that should be carefully taken into account; and call for joint, immediate, and interdisciplinary efforts and collaborations to start on the path toneeds-awareAI.


  • Open Access

    Abstract 3094: Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models

    by Ryan Watkins, Roberto Alva-Ruiz, Caitlin Conboy, Dong-Gi Mun, Erik Jessen, Diep Vu, Jos de Man, Rogier Buijsman, Akhilesh Pandey, Mitesh Borad, et al.

    Background: Cholangiocarcinoma is an aggressive malignancy with limited systemic therapeutics. We have recently identified LCK, a non-receptor tyrosine kinase, as a potential therapeutic target in select subtypes of cholangiocarcinoma. Proteomic profiling in other cancer types has proven beneficial in predicting response to systemic therapies. Herein, we present proteomic profiling of cholangiocarcinoma can predict sensitivity to a novel LCK inhibitor in patient derived xenograft models. Methods: Proteins from 28 unique cholangiocarcinoma patient derived xenograft models (PDX) were isolated, labeled with tandem mass tags (TMT) and then analyzed by liquid chromatography and mass spectroscopy (LC/MS). Phosphopeptides were separately evaluated both by Immobilized Metal Affinity Chromatography and pY-enrichment techniques. Following normalization, the global proteome, serine/threonine phosphoproteome, and tyrosine phosphoproteome were analyzed and a proteomic signature was created for each tumor. These signatures were compared to PDX models with known response profiles to NTRC0652-0, an LCK inhibitor (1 resistant and 1 sensitive). The top 200 differentially abundant proteins (log2FC 2.6) were then utilized to develop a sensitive and a resistant signature. Correlation indices were then calculated across the 28 PDX model library. An additional predicted resistant and predicted sensitive model was expanded. Tumor bearing mice were randomized based on tumor volume to either treatment with NTRC (30mg/kg PO daily), n=5, or vehicle, n=4, (10% Kolliphor, 10% DMSO, 80% Water, 2 mol equivalents HCl). Tumors were measured weekly with calipers and then weighed at the end of the study. Results: In the top 200 differentially abundant proteins that represented the proteomic signature there was over representation of proteins with decreased abundance. There were only 12 proteins with higher abundance in the sensitive model as compared to the resistant. Utilizing the signature developed from the global proteomics data, nine tumors were predicted to be sensitive while 17 were predicted to be resistant to NTRC. PDX115 is a an intrahepatic CCA PDX known to contain an IDH1 mutation and was predicted to be resistant by modeling. The model was resistant to single agent NTRC with no demonstrable effect on tumor growth in vivo. PDX175 is a distal CCA PDX and was predicted to be sensitive by modeling. In vivo growth was inhibited by NTRC as compared to vehicle treated mice following two weeks of treatment (983% vs 435%, p=0.03). Additionally, final tumor weight was significantly lower in NTRC treated mice (0.651 g vs 0.317 g, p=0.04). Conclusion: Cholangiocarcinoma proteomic signatures can be used to predict therapeutic response to a novel LCK inhibitor in preclinical models. Whether or not this could be applied to other treatment modalities in cholangiocarcinoma remains to be determined. Citation Format: Ryan Watkins, Roberto Alva-Ruiz, Caitlin Conboy, Dong-Gi Mun, Erik Jessen, Diep Vu, Jos de Man, Rogier Buijsman, Akhilesh Pandey, Mitesh Borad, Gregory Gores, Rory Smoot. Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3094.

  • Open Access

    Needs-aware Artificial Intelligence: AI that 'serves [human] needs'

    by Ryan Watkins, Soheil Human

    By defining the current limits (and thereby the frontiers), many boundaries are shaping, and will continue to shape, the future of Artificial Intelligence (AI). We push on these boundaries in order to make further progress into what were yesterday's frontiers. They are both pliable and resilient - always creating new boundaries of what AI can (or should) achieve. Among these are technical boundaries (such as processing capacity), psychological boundaries (such as human trust in AI systems), ethical boundaries (such as with AI weapons), and conceptual boundaries (such as the AI people can imagine). It is within this final category while it can play a fundamental role in all other boundaries} that we find the construct of needs and the limitations that our current concept of need places on the future AI.


  • Open Access

    Needs and Artificial Intelligence

    by Soheil Human, Ryan Watkins

    Throughout their history, homo sapiens have used technologies to better satisfy their needs. The relation between needs and technology is so fundamental that the US National Research Council defined the distinguishing characteristic of technology as its goal "to make modifications in the world to meet human needs". Artificial intelligence (AI) is one of the most promising emerging technologies of our time. Similar to other technologies, AI is expected "to meet [human] needs". In this article, we reflect on the relationship between needs and AI, and call for the realisation of needs-aware AI systems. We argue that re-thinking needs for, through, and by AI can be a very useful means towards the development of realistic approaches for Sustainable, Human-centric, Accountable, Lawful, and Ethical (HALE) AI systems. We discuss some of the most critical gaps, barriers, enablers, and drivers of co-creating future AI-based socio-technical systems in which [human] needs are well considered and met. Finally, we provide an overview of potential threats and HALE considerations that should be carefully taken into account, and call for joint, immediate, and interdisciplinary efforts and collaborations.